04/15/14 - 12:23 PM EDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.READ FULL POST
04/11/14 - 03:07 PM EDT
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.READ FULL POST
04/10/14 - 01:09 PM EDT
Wednesday's mini rally was a head fake, leading to more selling Thursday.READ FULL POST
04/10/14 - 11:52 AM EDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.READ FULL POST
04/10/14 - 10:24 AM EDT
An explanation of Northwest Bio's "up to" $32 million financing deal.READ FULL POST
04/09/14 - 11:50 AM EDT
Documents pertaining to an upcoming pre-trial "Markman" hearing were made public which appear to favor Celgene over Natco, the generic drugmaker challenging certain Revlimid patents, according to an analyst.READ FULL POST
04/08/14 - 02:34 PM EDT
Sarepta executives met again with FDA officials in March to nail down a regulatory path for the Duchenne muscular dystrophy drug eteplirsen. The company has promised to update investors about the outcome of the FDA meeting, but without saying exactly when.READ FULL POST
04/08/14 - 11:23 AM EDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a coalition of private employers, insurance companies and the government focused on fair drug pricing. But first, Express wants Gilead to cut the price of Sovaldi or be frozen out when competing hepatitis C therapies are approved later this year and next, according to a Bloomberg report.READ FULL POST
04/08/14 - 09:11 AM EDT
If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.READ FULL POST
04/03/14 - 09:00 AM EDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.